Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone sodium phosphate
Drug ID BADD_D00625
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D00975
MeSH ID C004180
PubChem ID 16961
TTD Drug ID D0NA8U
NDC Product Code 50090-3300; 51662-1391; 63323-165; 67457-418; 67457-421; 70121-1399; 70121-1452; 70529-045; 76045-109; 0009-5027; 51662-1432; 55150-239; 71872-7091; 71872-7128; 71872-7153; 52128-159; 65089-0001; 82298-113; 52584-422; 55150-238; 63323-516; 67457-420; 70069-021; 70121-1450; 71872-7147; 70069-025; 70121-1451; 71872-7239; 72572-122; 51662-1297; 55150-304; 55150-305; 55154-9364; 67457-422; 67457-423; 71872-7157; 76420-077; 24002-0025; 51927-1430; 79572-013; 50090-3541; 0404-9843; 67457-419; 70518-3379; 70518-3458; 71872-7090; 0641-0367; 76045-210; 76420-270; 49452-2470; 63323-506; 70069-023; 70069-024; 70518-0410; 71872-7021; 72572-120; 0641-6145; 0641-6146; 51927-0135; 24208-720; 51662-1370; 51662-1541; 55154-5118; 0404-9841; 67457-483; 70518-1922; 70518-3724; 70529-118; 71872-7092; 71872-7164; 71872-7171; 71872-7205; 0404-9842; 68083-473; 68083-474; 70529-112; 76045-106; 76420-185; 80425-0261; 81565-202; 49452-2473; 57582-015; 52584-420; 67457-484; 70069-022; 70518-2936; 70518-3019; 76420-555; 38779-0071; 51552-0025; 60722-3014; 50090-2313; 51662-1343; 52584-239; 55150-237
UNII AI9376Y64P
Synonyms dexamethasone 21-phosphate | dexamethasone phosphate | dexamethasone 21-phosphate, monosodium salt, (11beta,16alpha)-isomer | dexamethasone sodium phosphate | dexamethasonedisodium phosphate | dexamethasone phosphate disodium salt | Solu- Decadron | Spersadex | Spersadox | dexamethasone 21-phosphate, (6alpha,11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (6alpha,11beta,16alpha)-isomer | Decadron phosphate | dexamethasone 21-phosphate, sodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, copper (+2) salt (2:3), (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C22H28FNa2O8P
CAS Registry Number 2392-39-4
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+ ]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Alkalosis hypokalaemic14.01.02.002---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Carbohydrate tolerance decreased13.02.02.003---
Cardiac failure congestive02.05.01.002---
Cataract subcapsular06.06.01.002---
Cushingoid05.01.01.002; 14.11.01.006; 19.07.03.001; 24.08.02.004--
Dermatitis allergic10.01.03.014; 23.03.04.003---
Diabetes mellitus05.06.01.001; 14.06.01.001---
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002---
Erythema23.03.06.001---
Exophthalmos05.02.02.002; 06.09.04.001---
Fluid retention14.05.06.002; 20.01.02.003---
Glaucoma06.03.01.002--
Headache17.14.01.001--
Hiccups07.01.06.009; 22.12.01.001--
Hirsutism05.05.01.005; 23.02.04.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypokalaemic syndrome14.05.03.003---
Hypothalamo-pituitary disorder05.03.04.003---
Impaired healing08.03.02.001---
Increased appetite08.01.09.027; 14.03.01.003---
Increased insulin requirement05.06.01.006; 14.06.01.006---
Intracranial pressure increased17.07.02.002---
Intraocular pressure increased13.07.04.002---
Large intestine perforation07.04.06.005; 12.02.03.005--
The 1th Page    1 2 3    Next   Last    Total 3 Pages